Search For "serum institute of india"
DCGI approves India's first qHPV vaccine to treat cervical cancer
Updated : 4 years ago IST
New Delhi [India], July 12 (ANI): India's first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer gets Drugs Controller General of India (DCGI) approval for market authorisation. This vaccine will be manufactured by the Serum Institute of India (SII).
Read More
SII's Covovax gets DCGI emergency use nod for children between 7-12 years
Updated : 4 years ago IST
New Delhi [India], June 28 (ANI): The Drugs Controller General of India (DCGI) has given restricted emergency use authorisation (EUA) to Pune-based Serum Institute of India's COVID-19 vaccine 'Covovax' for children aged 7 to 12 years, sources told ANI.
Read More
SEC recommends India's first indigenously developed vaccine against cervic
Updated : 4 years, 1 month ago IST
New Delhi [India], June 15 (ANI): The subject expert committee meeting that was scheduled today to discuss Serum Institute of India's (SII) indigenously developed Quadrivalent human papillomavirus (qHPV) vaccine against cervical cancer, has recommended regular market authorisation for above
Read More
SEC to discuss India's first indigenously developed vaccine against cervic
Updated : 4 years, 1 month ago IST
New Delhi [India] June 15 (ANI): The first indigenously developed quadrivalent human papillomavirus (qHPV) vaccine against cervical cancer by the Serum Institute of India (SII) will be discussed by the Subject expert committee on Wednesday.
Read More
Adar Poonawalla clarifies COVID-19 vaccine Covovax available for everyone
Updated : 4 years, 2 months ago IST
Pune (Maharashtra) [India], May 5 (ANI): Chief Executive Officer of Pune based Serum Institute of India Adar Poonawalla on Wednesday clarified that the COVID-19 vaccine Covovax is available for everyone above the age of 12 years.
Read More
COVID-19 vaccine Covovax now available for children in India: Adar Poonawa
Updated : 4 years, 2 months ago IST
New Delhi [India], May 3 (ANI): Serum Institute of India (SII) CEO Adar Poonawalla on Tuesday said that the COVID-19 vaccine Covovax is now available in India for children.
Read More
SEC seeks more data from Serum Institute over COVID vaccine Covovax for 7-
Updated : 4 years, 2 months ago IST
New Delhi [India], April 30 (ANI): The Drugs Controller General of India's (DCGI) subject expert committee on Friday sought more data from Pune based Serum Institute of India (SII) on the Covovax vaccine for the age group of 7-12 years.
Read More
NTAGI approves SII's Covovax COVID vaccine for 12-17 age group: Sources
Updated : 4 years, 2 months ago IST
New Delhi [India], April 29 (ANI): National Technical Advisory Group on Immunisation (NTAGI) on Friday approved Serum Institute of India's Covovax COVID-19 vaccine for the age group 12-17, said sources.
Read More
Indian jab in my arms, says UK PM; hails COVID-19 vaccine collaboration
Updated : 4 years, 2 months ago IST
New Delhi [India], April 22 (ANI): British Prime Minister Boris Johnson on Friday highlighted the collaboration between Oxford-Astra Zeneca and the Serum Institute of India (SII) for the production of COVID-19 vaccines and emphasised that he has "the Indian jab" in his arms.
Read More
Poonawalla Fincorp enters digital consumption loans space
Updated : 4 years, 2 months ago IST
Pune (Maharashtra) [India] April 19 (ANI/BusinessWire India): Poonawalla Fincorp Limited (Formerly Magma Fincorp Limited), has entered digital consumption loans space through a tie-up with KrazyBee. Under this partnership, Poonawalla Fincorp will offer small ticket personal loans to individu
Read More
Indian COVID vaccines better than Pfizer, Moderna says Adar Poonawalla
Updated : 4 years, 3 months ago IST
New Delhi [India], April 13 (ANI): Serum Institute of India (SII) CEO Adar Poonawalla on Wednesday claimed that "Made in India" COVID-19 vaccines have provided more protection against the coronavirus infection than mRNA vaccines like Pfizer and Moderna.
Read More
India is now better prepared to fight any Covid-19 variant, says SII's Ada
Updated : 4 years, 3 months ago IST
New Delhi [India], April 12 (ANI): As some countries are presently reporting higher COVID-19 cases, Chief Executive Officer of Serum Institute of India (SII) Adar Poonawalla on Tuesday said that India is better prepared to face it now than it was in 2020.
Read More